NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM




- Sep 27, 2022
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma


- Sep 23, 2022
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM


- Sep 1, 2022
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)


- Jun 11, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma


- Mar 1, 2022
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma


- Mar 1, 2022
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma


- Mar 1, 2022
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)


- Mar 1, 2022
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6


- Dec 16, 2021
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma


- Dec 3, 2021
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3


- Dec 1, 2021
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM


- Dec 1, 2021
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM


- Aug 31, 2021
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex


- Aug 6, 2021
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER


- Jun 28, 2021
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma


- Jun 26, 2021
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)


- Jun 17, 2021
NCT04776018: Phase 1/2: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In RRMM


- Jun 11, 2021
NCT04895410: Phase 1 -IV Lemzoparlimab +/- Oral/IV Dex plus Oral/IV/SC Anti-Myeloma Regimens


- Jun 9, 2021
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma


- Jun 1, 2021
NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma


- Dec 17, 2020
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide


- Dec 12, 2020
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181


- Dec 10, 2020
NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)

- Dec 9, 2020
NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies


- Jul 18, 2020
NCT04407442: Phase 2: Dara, Azacitidine & Dex for RRMM Myeloma Previously Treated With Daratumumab


- Jul 16, 2020
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd


- Jul 11, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)


- Jul 8, 2020
NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure


- Dec 30, 2019
NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years


- Dec 27, 2019
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)


- Dec 20, 2019
The MAMMOTH study: Monoclonal Antibodies in Multiple Myeloma: Outcomes after Therapy Failure


- Dec 19, 2019
NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis


- Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)


- Dec 14, 2019
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC


- Dec 14, 2019
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM


- Dec 13, 2019
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM


- Dec 13, 2019
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara

- Dec 13, 2019
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma


- Dec 12, 2019
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM


- Dec 11, 2019
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002


- Dec 11, 2019
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines


- Dec 11, 2019
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2


- Dec 6, 2019
NCT03993912: Phase 3 - Lenalidomide & SC Daratumumab vs Lenalidomide and Dex in NDMM - (IFM2017_03)


- Dec 6, 2019
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM


- Dec 6, 2019
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dex or Daratumumab, Bortezomib, & Dex in NDMM Myeloma


- Dec 6, 2019
NCT03871829: Phase 2: Retreatment in Participants With Myeloma Who Have Been Previously Rx with Dara


- Dec 4, 2019